Baseline Findings from Dual-Phase Amyloid PET Study in Newly Diagnosed Multiple Sclerosis: Exploring Its Potential as a Biomarker of Myelination and Neurodegeneration

Barrios-López, Jose María; Triviño-Ibañez, Eva María; Piñeiro-Donis, Adrian; Segovia-Román, Fermin; Pérez García, Maria del Carmen; Marín-Romero, Bartolomé; Romero Villarrubia, Ana; Guillén Martínez, Virginia; Martinez-Barbero, José Pablo; PIñar Morales, Raquel; Barrero Hernández, Francisco Javier; Minguez-Castellanos, Adolfo; Gómez-Rio, Manuel

doi:10.3390/jpm15110520

jpm-15-00520-Barrios-PET.pdf (1.481Mb)

Identificadores

URI: https://hdl.handle.net/10481/107702

DOI: 10.3390/jpm15110520

Exportar

Editorial

MDPI

Fecha

2025-11-01

Referencia bibliográfica

Barrios-López, J.M.; Triviño-Ibáñez, E.M.; Piñeiro-Donis, A.; Segovia-Román, F.; Pérez García, M.d.C.; Marín-Romero, B.; Romero Villarrubia, A.; Guillén Martínez, V.; Martínez-Barbero, J.P.; Piñar Morales, R.; et al. Baseline Findings from Dual-Phase Amyloid PET Study in Newly Diagnosed Multiple Sclerosis: Exploring Its Potential as a Biomarker of Myelination and Neurodegeneration. J. Pers. Med. 2025, 15, 520. https://doi.org/10.3390/jpm15110520

Colecciones

DMed - Artículos

Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional